BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue
Competitive Landscape Also Changing
Executive Summary
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.
You may also be interested in...
China 'No' For Celgene's Paclitaxel A Major Blow To BeiGene
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.